Short answer
AVANOS MEDICAL, INC. (AVNS) filed an 8-K current report with the SEC on July 15, 2026 reporting Item 8.01 (Other Events). Merger remains scheduled for July 22, 2026, with the board continuing its unanimous recommendation for the $25.00-per-share transaction.
AVANOS MEDICAL, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Merger remains scheduled for July 22, 2026, with the board continuing its unanimous recommendation for the $25.00-per-share transaction
- Two lawsuits seek to enjoin the merger, while stockholder demand letters allege proxy disclosure deficiencies
- Avanos supplemented disclosures to reduce litigation and closing-delay risk without admitting liability or changing merger terms
- UBS may receive up to $5 million upon closing, alongside disclosed prior and potential relationships with AIP and other sponsors
- JPMorgan valuation ranges of $12.75–$23.50 and $9.75–$21.75 remain below the $25.00 merger consideration
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AVANOS MEDICAL, INC. 8-K filings
Get the next AVNS 8-K as it lands
Follow AVNS for push alerts, or ask the research agent what this filing means.